Antiphospholipid antibodies in pulmonary embolism treated with direct oral anticoagulants: Prevalence data from unselected consecutive patients

BACKGROUND: Direct oral anticoagulants (DOACs) are the first-choice treatment option for the prevention of the recurrence of venous thrombosis in patients with pulmonary embolism (PE); however, their effect in patients with antiphospholipid syndrome (APS) is challenged. Therefore, the prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Justinussen, Tummas, Gram, Jorgen Brodersen, Bor, Mustafa Vakur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925606/
https://www.ncbi.nlm.nih.gov/pubmed/36798898
http://dx.doi.org/10.1016/j.rpth.2023.100050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925606/
https://www.ncbi.nlm.nih.gov/pubmed/36798898
http://dx.doi.org/10.1016/j.rpth.2023.100050

Ejemplares similares